237 related articles for article (PubMed ID: 32086574)
1. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
[TBL] [Abstract][Full Text] [Related]
2. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Adenoma Subtypes Based on 2017 Classification System: Exploratory Study of Gadoxetate Disodium-Enhanced MRI Features With Proposal of a Diagnostic Algorithm.
Tse JR; Felker ER; Cao JJ; Naini BV; Liang T; Lu DSK; Raman SS
AJR Am J Roentgenol; 2023 Apr; 220(4):539-550. PubMed ID: 36169546
[No Abstract] [Full Text] [Related]
4. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
[TBL] [Abstract][Full Text] [Related]
5. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
[TBL] [Abstract][Full Text] [Related]
6. Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.
Tse JR; Naini BV; Lu DS; Raman SS
Radiology; 2016 Apr; 279(1):118-27. PubMed ID: 26505921
[TBL] [Abstract][Full Text] [Related]
7. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
[TBL] [Abstract][Full Text] [Related]
8. Subtyping of hepatocellular adenomas using Gd-EOB-DTPA: a qualitative and quantitative analysis.
Schaible J; Schreyer AG; Mehrabi A; Longerich T; Kieser M; Kreimeyer S; Klauss M; Grenacher L
Acta Radiol; 2023 Jul; 64(7):2253-2260. PubMed ID: 36650712
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
[TBL] [Abstract][Full Text] [Related]
10. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
11. Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5
Auer TA; Halskov S; Fehrenbach U; Nevermann NF; Pelzer U; Mohr R; Hamm B; Schöning W; Horst D; Ihlow J; Geisel D
Eur Radiol; 2023 Oct; 33(10):6902-6915. PubMed ID: 37115216
[TBL] [Abstract][Full Text] [Related]
12. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular adenoma subtyping by qualitative MRI features and machine learning algorithm of integrated qualitative and quantitative features: a proof-of-concept study.
Liu X; Espin-Garcia O; Khalvati F; Namdar K; Fischer S; Haider MA; Jhaveri KS
Clin Radiol; 2023 Sep; 78(9):679-686. PubMed ID: 37365116
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
16. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
17. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
18. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
[TBL] [Abstract][Full Text] [Related]
19. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
[TBL] [Abstract][Full Text] [Related]
20. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
